SILVER SPRING
Dupixent cleared for pediatric chronic spontaneous urticaria
- Sponsor
- Sanofi and Regeneron
- Drug
- Dupixent · dupilumab
- Indication
- chronic spontaneous urticaria in children
FDA approved Dupixent (dupilumab) for children aged two to 11 years with chronic spontaneous urticaria who remain symptomatic despite antihistamine treatment.
What this means
Dupixent is an injectable antibody drug that blocks two proteins involved in allergic inflammation, helping control symptoms like hives and itching. Today FDA approved Dupixent for children aged two to 11 with chronic spontaneous urticaria who still have symptoms after taking antihistamines. This decision could provide younger patients with a new treatment option for persistent hives that don’t respond to standard therapies.
Drug Watch — recent news on Dupixent
- Regeneron stock trades steady as Eylea and Dupixent growth support earnings - ad-hoc-news.de
- Attovia files for IPO to take on Sanofi and Regeneron’s Dupixent - Fierce Biotech
- Evaluating Biologic Options and Monitoring Response in CSU - HCP Live
- Cutaneous T-cell lymphoma in adult atopic dermatitis patients treated with dupilumab or tralokinumab - Springer Nature Link
- People With Atopic Eczema Stick With Dupilumab Longer - Medscape
Sponsor Watch — recent news on Sanofi and Regeneron
- Regeneron Pharmaceuticals (REGN) Rebounds As Undervalued View Holds, Is The Upside Already Priced In?
- Merck Snags A First-Of-Its-Kind Approval, And Shares Jump
- Merck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pill
- Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside
- 1 Large-Cap Stock with Exciting Potential and 2 We Turn Down